AsemconnectVietnam - According to the recent Vietnam Report, Bidiphar (DBD) is in the top 5 reputable pharmaceutical manufacturing companies in 2023. The company's goal by 2030 is to reach the revenue threshold of VND5,000 billion. , is in the top 3 domestic pharmaceutical companies.

It is known that the Top reputable Pharmaceutical Companies are built on scientific and objective principles, based on 3 main criteria: financial capacity shown on the most recent year's financial statements; Media reputation and survey of relevant subjects were conducted in October-November 2023.
Overall, in the first 10 months of 2023, positive colors still play a leading role in the business results of businesses in the industry, with the majority of pharmaceutical businesses stabilizing and maintaining growth in revenue and profit. In particular, the hospital channel (ETC - prescription drugs) has good growth, mainly thanks to the loosening and more open drug bidding regulations in hospitals. As for the OTC (non-prescription drugs) segment, which went sideways, many businesses suffered a slight decline as this market is still in a mixed state.
With Bidiphar, the third quarter of 2023 recorded net revenue of VND411 billion (ETC channel accounts for 63%), pre-tax profit of VND76 billion. Accumulated in the first 9 months of the year, this pharmaceutical manufacturing company's revenue reached VND1,207 billion, an increase of 11% over the same period and net profit of 210 billion VND, an increase of 28%. With this result, DBD achieved 67% of the revenue plan and 84% of the profit plan. According to the business, it will achieve the profit target set out in the 2023 Annual General Meeting of Shareholders.
Considering the revenue structure by product, cancer treatment drugs, peritoneal solutions, blood filtration, anti-infection, pain relievers, fever reducers, and vitamins are DBD's main products contributing 68% of total revenue.
Regarding the business plan, DBD sets a revenue target of 2024 reaching VND2,000 billion, moving towards VND5,000 billion by 2030, of which VND4,500 billion is produced by the company. The company will also develop a research center according to ICH Q8 regulations. Bidiphar sets a vision that by 2026, the unit will be in the Top 5 domestic pharmaceutical manufacturing companies and rise to the Top 3 by 2030.
Bidiphar will prioritize R&D and receive technology transfer for the production of key products such as cancer treatment drugs, dialysis solutions, antibiotics and specialized drugs. The company also focuses on developing products from organic medicinal herbs with a total area of 75 hectares. The EU GMP standard approval process for Nhon Hoi cancer drug factory is expected to be carried out in late 2024 - early 2025.
Recently, Binh Dinh province issued a decision approving Bidiphar's small volume sterile medicine factory project at Lot A3.03, Nhon Hoi Economic Zone, Nhon Hoi commune, Quy Nhon City. The company will officially start the project in early December.
This is an investment project to build a new factory producing injectable drugs, eye drops and other sterile drugs according to GMP-EU standards; scale of 120 million products/year (equivalent to 1,600 tons/year).
Total investment capital is VND840 billion. Of which, Bidiphar contributed VND700 billion in cash (accounting for 100% of capital contribution). Revenue in 2027 is expected to reach nearly VND581 billion and increase to VND1,685 billion in 2031.
DBD is known as one of the leading pharmaceutical research, production and sales companies in Vietnam. With a widespread distribution system, Bidiphar's products have been supplied to more than 22,000 customers nationwide and exported abroad.
According to Ms. Pham Thi Thu Huong, General Director of Bidiphar at the September event, the company will focus on cancer treatment drugs, especially pills (expected roadmap is 2024 to submit registration documents, 2025 has registration number, 2026 production).
Bidiphar's next development direction is to focus on researching targeted drugs in cancer treatment, especially pills. Third is to gradually receive technology transfer and deploy the production of biotechnology drugs to treat cancer.
With the dialysis solution product line, the Company is researching to create a difference, and at the same time researching and creating additional products for kidney failure patients.
With antibiotics and specific drugs, new generation antibiotics will be researched. In addition, DBD will focus on eye drops, and special medications for cardiovascular and diabetes treatment.
N.Nga
Source: VITIC/Tinnhanhchungkhoan